Abstract

The Virginia Mason Medical Center (VMMC) is a multispecialty regional care center which provides a multidisciplinary approach to cancer care and recognizes clinical research as an important component of a cancer care program. The VMMC is seeking funding through the Community Clinical Oncology Program (CCOP) to support its participation in a broad range of clinical research protocols utilizing the Southwest Oncology Group (SWOG), the Radiation Therapy Oncology Group (RTOG), and the Fred Hutchinson Cancer Research Center (FHCRC) as its research bases. A total of 102 patients will be entered on protocols--SWOG, 57 patients; RTOG, 16 patients: and, FHCRC, 19 patients. The investigators have extensive experience in cooperative clinical research studies through prior membership in the Cancer and Leukemia Group B; current membership in the National Prostatic Cancer Project, the National Bladder Cancer Collaborative Group A, and the Lung Cancer Study Group; and recent unfunded membership in the SWOG. A cooperative arrangement will also be established between the oncologists at VMMC and Valley General Hospital (VGH), Renton, Washington, which will enable VGH patients with cancer to participate in cooperative clinical trials and will promote the development of the VGH cancer care program.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035192-03
Application #
3557602
Study Section
(SRC)
Project Start
1983-09-01
Project End
1987-08-31
Budget Start
1985-09-01
Budget End
1987-08-31
Support Year
3
Fiscal Year
1985
Total Cost
Indirect Cost

  Institution

Name
Benaroya Research Institute at Virginia Mason
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98101

  Publications

Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Mata, Douglas A; Groshen, Susan; Von Rundstedt, Friedrich-Carl et al. (2015) Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol 111:923-8
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
von Rundstedt, Friedrich-Carl; Mata, Douglas A; Groshen, Susan et al. (2015) Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int 116:44-9
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7

Showing the most recent 10 out of 131 publications